SLC5A2 and heart failure: SGLT2 inhibitors, which are used to treat heart failure regardless of diabetes status, have been shown in cardiovascular outcome trials to reduce the risk of major adverse cardiovascular events, cardiovascular death, and heart failure (62, 63).